<DOC>
	<DOCNO>NCT02087384</DOCNO>
	<brief_summary>This study evaluate vaccination quadrivalent HPV vaccine ( Gardasil ) versus placebo vaccination prevention high grade AIN recurrence HIV-positive MSM ( men sex men ) successfully treat high grade AIN .</brief_summary>
	<brief_title>HPV ( Human Papilloma Virus ) Vaccination After Treatment Anal Intraepithelial Neoplasia ( AIN )</brief_title>
	<detailed_description>Rationale : Since introduction combination antiretroviral therapy ( cART ) , human immunodeficiency virus ( HIV ) -related morbidity mortality considerably decrease . However , result significantly prolong life span , new cause morbidity mortality become evident . In particular , anal cancer incidence increase dramatically HIV-positive men . Like cervical cancer , anal cancer causally link infection high-risk papillomaviruses , precede precursor lesion : anal intraepithelial neoplasia ( AIN ) . Over 90 % HIV-positive MSM ( men sex men ) persist anal HPV ( human papilloma virus ) infection , high-grade ( HG ) AIN present 30 % HIV+ MSM . As cervical intraepithelial neoplasia , early diagnosis treatment AIN advocate prevent malignancy . Electrocoagulation/ cauterization standard care intra-anal AIN , treatment , recurrence lesion occur approx . 50 % case . This major problem effective screening program AIN . In nonconcurrent , non-blinded cohort study qHPV ( quadrivalent human papilloma virus ) vaccination significantly ( HR 0.50 ) reduce HG AIN recurrence among MSM successfully treat AIN . This accordance finding woman treat cervical intraepithelial neoplasia . Previous vaccination quadrivalent HPV vaccine among woman surgical treatment HPV relate disease significantly reduce incidence subsequent HPV related disease , include high grade disease . Therefore , strategy worth investigate vaccination qHPV vaccine prevent recurrence HIV+ MSM successfully treat HG AIN . Objective : The primary objective current study ass efficacy qHPV vaccination prevent recurrence high-grade AIN HIV+ MSM CD4 count &gt; 350 x 10E6/l successfully treat high-grade intra-anal AIN past year . Study population : HIV-positive MSM CD4 count &gt; 350 cells/ul intra-anal high-grade AIN ( grade 2-3 ) successfully treat past year conventional cauterization , cryotherapy , form local treatment . Study design : A multicenter , randomise , double-blind clinical trial four hospital Netherlands . Intervention : Patients randomise vaccination quadrivalent HPV vaccine ( Gardasil ® ) vaccination match placebo month 0 , 2 6 . Randomisation stratify complete response versus partial response ( HG AIN low-grade ( LG ) AIN ) initial HG AIN lesion , treatment le 6 month ago versus treatment 6 month longer ago , AMC versus hospital . Main study parameters/endpoints : Screening AIN perform high-resolution anoscopy ( HRA ) , inclusion ( first vaccination ) last vaccination ( 6 month ) , repeat 6 12 month last vaccination . Safety Monitoring adverse event injection-site reaction perform one week vaccination thereafter every 6 month total 12 month follow-up . Primary end point cumulative recurrence HG AIN 12 month last vaccination , assess HRA ( High-Resolution Anoscopy ) , biopsies take suspect lesion . Secondary outcome measure toxicity/ safety , recurrence HG AIN last vaccination 6 month afterwards , cumulative occurrence LG AIN 12 month last vaccination , cumulative occurrence anogenital warts 12 month last vaccination , causative HPV type recurrent AIN lesion , assess LCM ( Laser Capture Microdissection ) / PCR ( polymerase chain reaction ) , HPV type-specific antibody response . The total sample size estimate 125 patient base expect recurrence rate 50 % within 12 month . Statistical analysis base intention-to-treat principle . Both primary secondary endpoint analyze descriptive statistic chi-square test 0,05 two-sided significance level . Nature extent burden risk associate participation , benefit group relatedness : HIV+ MSM successfully treat HG AIN still 50 % risk recurrence , additional treatment session need , ongoing risk malignant degeneration lesion . Costs 3 vaccination approx . € 400 , vaccination reduces recurrence rate 50 % , highly cost-effective intervention , likely introduce regular care . For study , patient vaccinate 3 time quadrivalent vaccine Gardasil ® placebo , undergo two extra HRAs . Clinical trial data show common adverse event Gardasil ® mild moderate , risk associate study participation .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent . Age ≥ 18 year . HIV+ MSM , CD4 count &gt; 350/ul ( maximum 6 month screen visit ) . Biopsyproven intraanal highgrade AIN successfully treat past year cauterization , cryotherapy , Efudix , imiquimod another form local treatment . A maximum interval 1 year last treatment first vaccination allow . Lesions regression HG LG AIN ( AIN 1 ) also eligible . Lesions ( still ) remission : Remission establish 2 independent HRA anoscopists . A maximum interval 3 month allow first HRAs first vaccination , maximum interval 6 week allow second HRAs first vaccination . Biopsies suspect lesion need obtain one HRA session . Good performance status ( Karnofsky performance score ≥ 60 [ scale 0 100 , high score indicate good performance status ] ) . Pretreatment haematology , plasma ASAT , ALAT creatinine level compatible study inclusion ( maximum 6 week screen visit ) . Exclusion criterion : Immunosuppressive medication disease associated immunodeficiency . Life expectancy less one year . Previous HPV vaccination . History anal cancer . Other disease compatible study participation . Allergy constituent Gardasil ® vaccine . Currently perianal AIN2 3 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Anal intraepithelial neoplasia</keyword>
	<keyword>HIV</keyword>
	<keyword>HPV</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Gardasil</keyword>
	<keyword>Prophylactic</keyword>
</DOC>